Unique ID issued by UMIN | UMIN000035489 |
---|---|
Receipt number | R000040433 |
Scientific Title | Effectiveness of near-infrared spectroscopy neurofeedback for psychiatric disorders |
Date of disclosure of the study information | 2019/01/10 |
Last modified on | 2020/12/23 17:33:26 |
Effectiveness of near-infrared spectroscopy neurofeedback for psychiatric disorders
Effectiveness of NIRS-based neurofeedback
Effectiveness of near-infrared spectroscopy neurofeedback for psychiatric disorders
Effectiveness of NIRS-based neurofeedback
Japan |
Major depression, Bipolar disorder, Anxiety disorder, Autism spectrum disorder, Attention-deficit/hyperactivity disorder, and Healthy control
Psychiatry |
Others
NO
The therapeutic effect of antidepressants for depression is reported to be about 30% in remission rate. Other treatments include electroconvulsive therapy (ECT), recurrent transcranial magnetic stimulation (rTMS), deep brain stimulation (DBS) but they have disadvantages of high invasiveness.
Neurofeedback (NFB) is an emergent approach that has been adopted in recent years as a potential intervention for a number of psychiatric disorders. In the NFB study using fMRI, it has been reported that clinical symptoms of mental disorders may be improved by repeating the training to change the neural activity of a specific brain region associated with disease.
In recent years, NFB research using NIRS has also been observed (Kinoshita et al., 2016). As a mechanism of NIRS-based NFB, we aim to improve the neural network impairments that connect the frontal lobe, limbic system, and the basal ganglia directly by continuing training to selectively activate an region of the frontal lobe.
In this study, we aim to establish the usefulness of NFB training by NIRS for psychiatric disorders.
Efficacy
1 Clinical evaluation scale
HAM-D, HAM-A, MADRAS, etc.
2 Neuropsychological examination
TMT, BADS, CAT, CANTAB, etc.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Self control
1
Treatment
Device,equipment |
We conduct a maximum of 20 NFB at a pace of 2-5 days per week.
16 | years-old | <= |
90 | years-old | >= |
Male and Female
1 Patient group
People who were diagnosed with major depression, bipolar disorder, anxiety disorder, ASD, ADHD in DSM-5
2 Healthy control group
A healthy person without a history of mental illness
People who satisfies one of the following
1 Combined circulatory organ, liver, kidney, respiratory organs, blood, endocrine, central nervous system diseases, and person who was judged to be extremely unstable
2 Person who has history of head trauma or substance dependence
3 People with a history of epilepsy or generalized convulsions
4 For healthy control subjects, those who are diagnosed with developmental disorder
300
1st name | Bun |
Middle name | |
Last name | Yamagata |
Keio University School of Medicine
Department of Neuropsychiatry
160-8582
35 Shinanomachi Shinjuku-Ku, Tokyo
03-5363-3971
yamagata@a6.keio.jp
1st name | Bun |
Middle name | |
Last name | Yamagata |
Keio University School of Medicine
Department of Neuropsychiatry
160-8582
35 Shinanomachi Shinjuku-Ku, Tokyo
03-5363-3971
yamagata@a6.keio.jp
Keio University School of Medicine
Self funding
Self funding
Keio University
35 Shinanomachi Shinjuku-Ku, Tokyo
03-5363-3503
med-rinri-jimu@adst.keio.ac.jp
NO
2019 | Year | 01 | Month | 10 | Day |
Unpublished
Open public recruiting
2019 | Year | 01 | Month | 08 | Day |
2019 | Year | 01 | Month | 20 | Day |
2019 | Year | 01 | Month | 22 | Day |
2024 | Year | 03 | Month | 31 | Day |
2019 | Year | 01 | Month | 08 | Day |
2020 | Year | 12 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040433